Literature DB >> 32803988

Severe Clostridium difficile colitis as potential late complication associated with COVID-19.

J Páramo-Zunzunegui1, I Ortega-Fernández1, P Calvo-Espino1, C Diego-Hernández2, I Ariza-Ibarra1, L Otazu-Canals1, J E Danés-Grases1, A Menchero-Sánchez1.   

Abstract

Spain has been one of the most affected countries by the COVID-19 outbreak. After the high impact of the pandemic, a wide clinical spectrum of late complications associated with COVID-19 are being observed. We report a case of a severe Clostridium difficile colitis in a post-treatment and recovered COVID-19 patient. A 64-year-woman with a one-month hospital admission for severe bilateral pneumonia associated with COVID-19 and 10 days after discharge presented with diarrhoea and abdominal pain. Severe C. difficile-associated colitis is diagnosed according to clinical features and CT findings. An urgent pancolectomy was performed due to her bad response to conservative treatment. Later evolution slowly improved to recovery. C. difficile-associated colitis is one of the most common hospital-acquired infections. Significant patient-related risk factors for C. difficile infection are antibiotic exposure, older age, and hospitalisation. Initial therapeutic recommendations in our country included administration broad-spectrum antibiotics to all patients with bilateral pneumonia associated with SARS-CoV-2. These antibiotics are strongly associated with C. difficile infection. Our patient developed a serious complication of C. difficile due to the use of broad-spectrum antibiotics. The appearance of late digestive symptoms in patients diagnosed and treated for COVID-19 should alert clinicians to the possibility of C. difficile infection. The updated criteria for severe colitis and severe C. difficile infection should be considered to ensure an early effective treatment for the complication.

Entities:  

Keywords:  2019 Novel coronavirus disease; COVID-19; Clostridium difficile infection; Colitis; Respiratory diseases; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spain; Toxic megacolon

Mesh:

Substances:

Year:  2020        PMID: 32803988      PMCID: PMC7450442          DOI: 10.1308/rcsann.2020.0166

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  7 in total

1.  COVID-19 and Fulminant Clostridium difficile Colitis Co-Infection.

Authors:  Abdul Ahad Ehsan Sheikh; Abu Baker Sheikh; Ishan Shah; Ali Hamza Khair; Nismat Javed; Rahul Shekhar
Journal:  Eur J Case Rep Intern Med       Date:  2021-08-24

Review 2.  Digestive involvement in the Long-COVID syndrome.

Authors:  Alina M Bogariu; Dan L Dumitrascu
Journal:  Med Pharm Rep       Date:  2022-01-31

Review 3.  Empiric Antibiotics in COVID 19: A Narrative Review.

Authors:  Elvina C Lingas
Journal:  Cureus       Date:  2022-06-02

Review 4.  Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use.

Authors:  Ravina Kullar; Stuart Johnson; Lynne V McFarland; Ellie J C Goldstein
Journal:  Antibiotics (Basel)       Date:  2021-04-09

5.  The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis.

Authors:  Guido Granata; Nicola Petrosillo; Samir Al Moghazi; Emanuela Caraffa; Vincenzo Puro; Glenn Tillotson; Maria Adriana Cataldo
Journal:  Anaerobe       Date:  2021-11-26       Impact factor: 2.837

6.  Prevalence and Health Outcomes of Clostridioides difficile Infection During the Coronavirus Disease 2019 Pandemic in a National Sample of United States Hospital Systems.

Authors:  Kelly R Reveles; Alexa L Frei; Kelsey A Strey; Eric H Young
Journal:  Open Forum Infect Dis       Date:  2022-08-25       Impact factor: 4.423

Review 7.  Clostridioides difficile infection (CDI) during the COVID-19 pandemic.

Authors:  Patrizia Spigaglia
Journal:  Anaerobe       Date:  2022-01-19       Impact factor: 2.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.